A Phase IIb Study to Evaluate the Dose Related Efficacy and Safety of QAW039 in Patients With Allergic Asthma Inadequately Controlled by Low-Dose Inhaled Corticosteroid Therapy

Trial Profile

A Phase IIb Study to Evaluate the Dose Related Efficacy and Safety of QAW039 in Patients With Allergic Asthma Inadequately Controlled by Low-Dose Inhaled Corticosteroid Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Fevipiprant (Primary) ; Montelukast
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jun 2016 New trial record
    • 18 May 2016 Primary endpoint has been met. (Change in pre-dose FEV1 at week 12 compared with placebo), as per results presented at the 112th International Conference of the American Thoracic Society.
    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top